IP Library Granted Patent US 8,778,921
Granted Patent B2
US 8,778,921 · App. 13/124,461 · Granted Jul 15, 2014

Ansamycin hydroquinone compositions

Inventors: James R. Porter (Rowley, MA); Sonali Puri (Ashland, MA)
Assignee: Infinity Pharmaceuticals, Inc.
A61K45/06A61K9/10A61K9/19A61K9/5026A61K31/395
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,778,921
App. No.
13/124,461
Granted
Jul 15, 2014
Kind
B2
Abstract

Aspects of the present invention provide compositions comprising a sulfur containing compound and a compound of the formula (I); and also provide methods of their preparation and use.

Claims (35)

1. A solid composition, comprising a sulfite; and a compound of formula (I):

wherein:

R 1 is —H, —OR 8 , —SR 8 —N(R 8 )(R 9 ), —N(R 8 )C(O)R 9 , —N(R 8 )C(O)OR 9 , —N(R 8 )C(O)N(R 8 )(R 9 ), —OC(O)R 8 , —OC(O)OR 8 , —OS(O) 2 R 8 , —OS(O) 2 OR 8 , —OP(O) 2 OR 8 or —CN;

each of R 2 and R 3 is, independently, selected from —H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, aralkyl, heteroaryl, heteroaralkyl, or —C(═O)CH 3 ; or R 2 and R 3 taken together with the nitrogen to which they are bonded represent a 3- to 8-membered heterocyclyl ring which contains 1 to 3 heteroatoms selected from O, N, S, and P;

R 4 is —H, alkyl, alkenyl or aralkyl;

R 5 and R 6 are each —H, or R 5 and R 6 taken together form a bond;

R 7 is —H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, aralkyl, heteroaryl, or heteroaralkyl; and

each instance of R 8 and R 9 is, independently, selected from —H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, aralkyl, heteroaryl, or heteroaralkyl; or R 8 and R 9 taken together represent a 3 to 8 membered optionally substituted heterocyclyl ring which contains 1 to 3 heteroatoms selected from O, N, S, and P;

the sulfur content of the composition is greater than 0.5 percent as measured by Elemental Analysis; at least about 80% of the original amount of the compound of formula (I) remains after said composition is stored for 14 days at 40° C. and 75% relative humidity; and

the sulfite is selected from the group consisting of potassium bisulfite, sodium bisulfite, calcium bisulfite, magnesium bisulfite, potassium metabisulfite, sodium metabisulfite, calcium metabisulfite, magnesium metabisulfite, potassium sulfite, sodium sulfite, calcium sulfite, magnesium sulfite, potassium hydrosulfite, sodium hydrosulfite, calcium hydrosulfite, magnesium hydrosulfite, and sodium formaldehyde sulfoxylate.

2. The composition according to claim 1 , wherein the compound is of the formula (I-a):

3. The composition according to claim 1 , wherein the compound is of the formula (I-b):

4. The composition according to claim 1 , wherein the compound is of the formula (I-c):

5. The composition according to claim 1 , wherein the compound is of the formula (I-d):

6. The composition of claim 5 , wherein R 2 is selected from the group consisting of —H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, aralkyl, heteroaryl and heteroaralkyl; and R 3 is —H.

7. The composition according to claim 6 , wherein R 2 is —H.

8. The composition according to claim 1 , wherein the compound of formula (I) is selected from the group consisting of:

9. The composition according to claim 1 , wherein the percent sulfur of the composition is greater than 1.0 percent as measured by Elemental Analysis.

10. A pharmaceutical formulation comprising a composition of claim 1 ; and a pharmaceutically acceptable excipient.

11. The formulation according to claim 10 , wherein the pharmaceutically acceptable excipient is a sugar.

12. The formulation according to claim 11 , wherein the sugar is selected from the group consisting of anhydrous lactose, lactose monohydrate, trehalose and hydroxypropyl-gamma-CD.

13. The formulation according to claim 10 , wherein the pharmaceutically acceptable excipient is a polymer.

14. The formulation according to claim 13 , wherein the polymer is polyvinyl alcohol.

15. The formulation according to claim 10 , wherein the pharmaceutically acceptable excipient is a surfactant.

16. The formulation according to claim 15 , wherein the surfactant is a Tween surfactant.

17. The formulation according to claim 10 , wherein the pharmaceutically acceptable excipient is an antioxidant.

18. The formulation according to claim 10 , wherein the pharmaceutically acceptable excipient is a solubilizing or suspending agent.

19. The formulation according to claim 18 , wherein the solubilizing or suspending agents is selected from the group consisting of water, organic solvents, oils, and mixtures thereof.

20. The formulation according to claim 10 , wherein the compound is of the formula (I-a):

21. The formulation according to claim 10 , wherein the compound is of the formula (I-b):

22. The formulation according to claim 10 , wherein the compound is of the formula (I-c):

23. The formulation according to claim 10 , wherein the compound is of the formula (I-d):

24. The formulation of claim 23 , wherein R 2 is selected from the group consisting of —H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, aralkyl, heteroaryl and heteroaralkyl; and R 3 is —H.

25. The formulation according to claim 24 , wherein R 2 is —H.

26. The formulation according to claim 10 , wherein the compound of formula (I) is selected from the group consisting of:

Assignments (2)
CHANGE OF NAME Recorded Jun 17, 2011
From: INFINITY DISCOVERY, INC.
To: INFINITY PHARMACEUTICALS. INC.
Reel/Frame 026464/0782 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2011
From: PORTER, JAMES R.; PURI, SONALI
To: INFINITY DISCOVERY, INC.
Reel/Frame 026417/0676 →
Continuity (2)
Provisional Application 61105648 · Oct 15, 2008
Related Publication 20110263563A1 · Oct 27, 2011